• Ibrutinib (PCI-32765): BTK Research Guide

  2026-09-23

  Ibrutinib, also called PCI-32765, is an irreversible BTK inhibitor for research on B-cell receptor signaling and B-cell biology. The product dossier reports a BTK IC50 of 0.5 nM and describes in vitro CLL effects, while emphasizing that assay conditions and clinical use are outside the product’s research scope.

• Firefly Luciferase mRNA: ARCA and 5-moUTP Guide

  2026-09-23

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is a modified, capped reporter transcript for luciferase-based gene expression, cell viability, and imaging workflows. This guide separates product specifications from peer-reviewed evidence and defines practical limits for interpreting bioluminescent signals.

• Telatinib Workflow for Angiogenesis Research

  2026-09-22

  Build a phenotype-centered workflow around Telatinib (BAY 57-9352) for endothelial tube formation, tumor-cell proliferation, and invasion studies. This guide emphasizes dose calibration, target attribution, DMSO control, and combination-assay design so antiangiogenic effects are not mistaken for nonspecific cytotoxicity.

• MIR9 Epigenetic Silencing in Acute Lymphoblastic Leukaemia

  2026-09-22

  The reference study links MIR9-family hypermethylation with reduced miR-9 expression, increased FGFR1 and CDK6 activity, and adverse outcomes in acute lymphoblastic leukaemia. Its combined clinical, epigenetic, and pharmacological evidence supports MIR9-regulated FGFR1 and CDK6 pathways as mechanistic and therapeutic research targets, while not establishing clinical efficacy for either inhibitor.

• Cabozantinib Adaptation in Renal Cell Carcinoma

  2026-09-21

  This 2026 study uses quantitative phosphoproteomics to show that acute and chronic Cabozantinib exposure produce distinct signaling states in renal cell carcinoma rather than a simple extension of the initial drug response. Persistent suppression of MET activation-loop phosphorylation coexisted with chronic adhesion-, stress-, and MAPK/AP-1-associated remodeling and modest, context-dependent motility changes.

• Cabozantinib: Temporal Signaling in RCC Models

  2026-09-21

  Cabozantinib research is moving beyond single-time-point potency measurements. This article explains how acute versus chronic exposure reshapes RCC phosphorylation networks and translates those findings into more discriminating assay decisions.

• Pazopanib and ATRX: A Translational RTK Strategy

  2026-09-20

  ATRX-deficient glioma models expose an important translational question: can biomarker-defined RTK dependence improve how researchers evaluate multi-targeted kinase inhibitors? This article connects the biology of ATRX loss with Pazopanib (GW-786034), practical assay design, pathway-level validation, and the strategic limits of translating class-level evidence into a compound-specific hypothesis.

• Dual HER2–VEGFR2 Targeting in TNBC Metastasis

  2026-09-19

  The reference study examines lapatinib and Telatinib (BAY 57-9352) as a dual-kinase strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its phenotype-centered findings—reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation—support further mechanistic testing but do not yet establish target engagement, formal drug synergy, or in vivo efficacy.

• Pazopanib in ATRX-Aware Cancer Research

  2026-09-18

  Pazopanib (GW-786034) is a multi-targeted kinase probe for dissecting angiogenesis, receptor signaling, and genotype-dependent drug response. This article presents a practical ATRX-aware assay framework that extends beyond conventional glioma sensitivity summaries.

• Aging, Mitochondrial ROS, and Macrophage Phagocytosis

  2026-09-18

  The reference study identifies a mechanistic link between aging, mitochondrial reactive oxygen species, collagen overproduction, and defective macrophage phagocytosis. Its combination of comparative phagocytic assays, RNA sequencing, COL1A1 manipulation, actin-interaction studies, and in vivo intervention provides a framework for testing how redox imbalance compromises innate immune function.

• AZD3463 ALK/IGF1R Inhibitor Workflows

  2026-09-17

  Build reproducible neuroblastoma assays around AZD3463, from DMSO preparation and ALK pathway readouts to combination testing with doxorubicin or temozolomide. The workflow separates product-backed performance from practical optimization and uses a TSSK2 kinase-screening study as a useful, clearly bounded assay-design precedent.

• Lyso-Tracker Red: Reliable Lysosome Assays

  2026-09-17

  Learn how Lyso-Tracker Red (SKU B8814) supports reproducible lysosome labeling in live cells, interpretation of cytotoxicity data, and fluorescence-based workflow optimization. This scenario-driven guide covers compatibility, protocol controls, data interpretation, and practical product selection.

• PD 173074: Mapping Stromal FGFR Escape

  2026-09-16

  PD 173074 is an ATP-competitive FGFR1 and VEGFR2 probe for investigating how stromal signals sustain tumor growth and drug resistance. This article presents a microenvironment-aware assay strategy grounded in ESCC research, with practical guidance for pathway validation, angiogenesis inhibition, and cancer research.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-16

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help interpret RTK inhibitor trials and prioritize temozolomide-based strategies, although clinical translation remains unproven.

• Adipose–CXCL5 Crosstalk in PDAC Immune Evasion

  2026-09-15

  The reference study identifies an obesity-associated signaling route in which adipose-derived IL-1β and TNF stimulate PDAC cells to secrete CXCL5, limiting CD8 T-cell entry into tumors. Its combination of patient-derived conditioned media, transcriptomics, cytokine assays, CRISPR perturbation, and syngeneic mouse models supports CXCL5 as a context-dependent immune-evasion mediator and suggests that ligand depletion may need checkpoint blockade to reduce tumor burden.

7440 records 1/496 page Next 12345 下5页 Last page